Figure (Image 01)
Myorisan
Product Images NDC 61748-304
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Myorisan (NDC 61748-304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Akorn Operating Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Image 02)
Versapharm Logo (Image 03)
Principal Display Panel (10 mg Prescription Blister Pack)
This appears to be a medication guide for Myorisan®, which is a medication for the treatment of severe acne. The guide provides important information for patients about the medication, including reminders of important safety facts, how to take the medication correctly, and what side effects to watch for. Patients who can become pregnant must sign informed consent forms before starting treatment due to the risk of causing serious birth defects. The text also lists potential side effects for patients taking the medication, as well as signs and symptoms of depression or other serious mental health problems.*
Principal Display Panel (20 mg Prescription Blister Pack)
This text is a warning and instructional document for patients who are prescribed the medication Myorisan®. It emphasizes the importance of reading all safety information provided with the prescription and of understanding how to take Myorisan® correctly and what the side effects are to watch for including serious birth defects. It warns patients who can get pregnant not to take Myorisan® to avoid severe birth defects and provides directions for patients on how to properly remove each capsule from its packaging. The document lists a range of commonly reported side effects and advises patients to tell their doctor if they experience any unusual symptoms. It also cautions that some users of Myorisan® have experienced serious mental health problems including depression, aggression, and suicidal thoughts.*
Principal Display Panel (30 mg Prescription Blister Pack)
Principal Display Panel (40 mg Prescription Blister Pack)
This is a package insert for a medication called Myorisan containing important safety information for patients, including risks of birth defects for pregnant women, and severe mental health side effects such as depression and suicide. It reminds patients to have a complete understanding of the medication's proper use and to contact their doctor if experiencing unusual physical or mental health symptoms.*
Image 08
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
